Početna › T-stanični limfom › Illinois
Kliničke studije za T-stanični limfom u državi Illinois
7 studija za T-stanični limfom traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
Službeni tekst studije (engleski)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Northwestern University, Chicago
- University of Illinois, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- i još 6
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Loyola Center for Health at Burr Ridge, Burr Ridge
- Loyola Medicine Homer Glen, Homer Glen
- Loyola University Medical Center, Maywood
- i još 1
U tijeku regrutacijaFaza 3
Od 18 do 75 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06724237A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04104776A Registry for People With T-cell Lymphoma
- Northwestern Medicine (Data Collection), Chicago
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 20. svi 2026. · NCT05978141Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2025. · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. pro 2024. · NCT05476770Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.